Royalty Pharma (RPRX)
(Delayed Data from NSDQ)
$26.86 USD
+0.42 (1.59%)
Updated Aug 13, 2024 04:00 PM ET
After-Market: $26.85 -0.01 (-0.04%) 7:58 PM ET
3-Hold of 5 3
B Value C Growth B Momentum B VGM
Brokerage Reports
[RPRX]
Reports for Purchase
Showing records 41 - 55 ( 55 total )
Industry: Medical - Biomedical and Genetics
MORNING CALL SUMMARY
Provider: Roth Capital Partners, Inc.
Industry: Medical - Biomedical and Genetics
MORNING CALL SUMMARY
Provider: Roth Capital Partners, Inc.
Industry: Medical - Biomedical and Genetics
Renewed Comfort on the Success of Androxal in Secondary Hypogonadism
Provider: Roth Capital Partners, Inc.
Analyst: JEN Y
Industry: Medical - Biomedical and Genetics
MORNING CALL SUMMARY
Provider: Roth Capital Partners, Inc.
Industry: Medical - Biomedical and Genetics
Industry: Medical - Biomedical and Genetics
MORNING CALL SUMMARY
Provider: Roth Capital Partners, Inc.
Industry: Medical - Biomedical and Genetics
MORNING CALL SUMMARY
Provider: Roth Capital Partners, Inc.
Industry: Medical - Biomedical and Genetics
Industry: Medical - Biomedical and Genetics
Industry: Medical - Biomedical and Genetics
Positive Proellex in UF Phase II Results Should Advance Phase III Studies
Provider: Roth Capital Partners, Inc.
Analyst: JEN Y
Industry: Medical - Biomedical and Genetics
MORNING CALL SUMMARY
Provider: Roth Capital Partners, Inc.
Industry: Medical - Biomedical and Genetics
MORNING CALL SUMMARY
Provider: Roth Capital Partners, Inc.
Industry: Medical - Biomedical and Genetics
The Second Time Could Be the Char-We are initiating coverage
Provider: Roth Capital Partners, Inc.
Analyst: JEN Y
Industry: Medical - Biomedical and Genetics
Dropping Coverage Due to Analyst Departure
Provider: WEDBUSH SECURITIES INC.
Industry: Medical - Biomedical and Genetics
IND for an Androxal Phase II Study OK?d by FDA; Study Design Not Finalized; Additional Capital Needed Prior to Initiation of Study.
Provider: WEDBUSH SECURITIES INC.
Analyst: LEE K